Table 3 Clinical outcomes of patients with DVT according to the use of IVCFs.

	PE with DVT				HR (95%CI)	P value
	With IVCF (n=39)		Without IVCF (n=281)
	n (%)	% per patient-year (95%CI)	n (%)	% per patient-year (95%CI)
Recurrence or aggravation of symptomatic VTE	1 (2.6)	1.6 (0.0–4.7)	13 (4.6)	2.8 (1.3–4.3)	0.58 (0.08–4.47)	0.601
Recurrence or aggravation of symptomatic PE	0	0	9 (3.2)	1.9 (0.7–3.2)	0	0.275
Recurrence or aggravation of symptomatic DVT	1 (2.6)	1.6 (0.0–4.7)	5 (1.8)	1.1 (0.1–2.0)	1.56 (0.18–13.40)	0.680
Acute coronary syndrome	0	0	1 (0.4)	0.2 (0.0–0.6)	0	0.716
Ischemic stroke	0	0	7 (2.5)	1.5 (0.4–2.6)	0	0.327
Death from any cause	4 (10.3)	6.3 (0.1–12.4)	21 (7.5)	4.4 (2.5–6.3)	1.42 (0.49–4.13)	0.522
Death related to VTE	0	0	3 (1.1)	0.6 (0.0–1.3)	0	0.531
Death related to CVD	0	0	4 (1.4)	0.8 (0.0–1.7)	0	0.473
Major bleeding	1 (2.6)	2.0 (0.0–6.0)	8 (2.8)	2.5 (0.8–4.3)	0.81 (0.10–6.49)	0.843
Minor bleeding	5 (12.8)	11.0 (1.4–20.6)	23 (8.2)	7.6 (4.5–10.8)	1.47 (0.56–3.88)	0.431

A P value of <0.05 was considered statistically significant. CI: confidence interval; CVD: cardiovascular disease; DVT: deep vein thrombosis; HR: hazard ratio; IVCF: inferior vena cava filter; PE: pulmonary thromboembolism; VTE: venous thromboembolism